NAUT: Rasio rega marang pendapatan Nautilus Biotechnology, Inc.
The price-to-sales valuation reflects the fierce competition for access to the laboratories of industry behemoths. The foundation of Nautilus Biotechnology (NAUT) is based on unique proteome mapping with immense pricing power potential, although the company is currently in an R&D phase without stable cash flow. Price action has resulted in the parameter stabilizing at 727.00.
Rincian analitis perusahaan Nautilus Biotechnology (NAUT)
- rega saham lan konsensus proyeksi valuasi:
- informasi kapitalisasi pasar:
- statistik nilai buku emiten:
- statistik kawajiban utang lan likuiditas:
Utang Agregat marang Modal Nautilus Biotechnology|NAUT - Utang jangka dawa marang modal|Kewajiban jangka cendhak marang modal nautilus.bio|NAUT - Gunggung utang perusahaan|Utang marang nilai buku Nautilus Biotechnology Inc|NAUT - Utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Nautilus Biotechnology|Rasio likuiditas darurat nautilus.bio
- data bathi resik lan rasio valuasi:
NAUT - Bathi resik perusahaan|Bathi resik sing dikarepake Nautilus Biotechnology|NAUT - Rasio rega marang bathi|Rega marang bathi mangsa ngarep nautilus.bio|NAUT - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Nautilus Biotechnology Inc|NAUT - Bathi operasional EBITDA|Bathi resik saben saham sajroning taun lumaku Nautilus Biotechnology|NAUT - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan nautilus.bio|NAUT - Wutah bathi saben saham ing taun lumaku|Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep Nautilus Biotechnology
- data total pendapatan lan volume dodolan:
Analisis umum perusahaan:NAUT (Nautilus Biotechnology, Inc.)
Nautilus Biotechnology (NAUT) is developing a high-precision proteome analysis system to identify the root causes of diseases. By analyzing the company's current P/S ratio, an investor assesses the market value of each unit of generated revenue. This ratio correlates the total market capitalization of the business with its actual operating income, determining the degree of the asset's overvaluation. A decline in this metric may signal either an undervaluation of the company's innovative potential or a systemic decline of the business.
Perusahaan pesaing
TEM (Tempus AI) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S QGEN (Qiagen)|Ionis Pharmaceuticals, Inc. - Rasio rega marang pendapatan|Repligen Corp. - Multiplikator P/S|Koefisien rega marang pendapatan Avidity Corp RNA|CRISPR Therapeutics AG (CRSP) - Rasio rega marang pendapatan|Rega marang dodolan genedx.com (WGS)|Kapitalisasi marang pendapatan RARE|BEAM (Beam Therapeutics Inc) - Kapitalisasi marang volume dodolan|Multiplikator P/S SRPT|TWST - Rega marang dodolan|Multiplikator P/S TXG (10x Genomics, Inc.)|NTLA - Kapitalisasi marang pendapatan|Stoke Therapeutics, Inc. - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan BLFS (BioLife Solutions Inc)|Wave Life Sciences Corp (WVE) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan MAZE|Rasio rega marang pendapatan Sionna Therapeutics Inc|Rega marang dodolan primemedicine.com PRME|Rasio rega marang pendapatan Taysha Gene Therapies, Inc. (TSHA)|Rasio rega marang pendapatan QURE (uniQure NV)|Rasio rega marang pendapatan MeiraGTx PLC MGTX|REGENXBIO Corp (RGNX) - Rega marang dodolan|Solid Biosciences Inc. - Multiplikator P/S|Multiplikator rega marang pendapatan ocugen.com (OCGN)|PACB (PacBio) - Kapitalisasi marang pendapatan|Rega marang dodolan Benitec Biopharma Inc (BNTC)|Rasio rega marang pendapatan Design Pharma|Rasio kapitalisasi marang pendapatan RCKT (Rocket Corp)|Multiplikator P/S FDMT|Multiplikator P/S lexeotx.com (LXEO)|Korro Bio - Kapitalisasi marang pendapatan|Multiplikator P/S Editas Medicine Inc EDIT|SLN: Kapitalisasi marang pendapatan|ProQR Therapeutics N.V. - Kapitalisasi marang volume dodolan|CDXS: Multiplikator P/S|Rasio kapitalisasi marang pendapatan SGMO|Rasio rega marang pendapatan Metagenomi|Rasio kapitalisasi marang pendapatan DTIL (precisionbiosciences.com)|Multiplikator P/S GBIO|Multiplikator P/S Boundless Bio Inc (BOLD)|Rasio rega marang pendapatan Exicure XCUR|IMNN: Rasio kapitalisasi marang pendapatan|RXi Pharmaceuticals - Multiplikator P/S|MBIO - Multiplikator P/S|RNAZ (transcodetherapeutics.com) - Kapitalisasi marang pendapatan|Bionano Genomics (BNGO) - Multiplikator P/S|Kapitalisasi marang pendapatan APDN|BLUE (bluebirdbio.com) - Kapitalisasi marang volume dodolan|Multiplikator P/S IPA|Koefisien rega marang pendapatan Omega Therapeutics Inc|Rasio rega marang pendapatan Singular Genomics Systems Inc OMIC|Regulus - Rasio rega marang pendapatan|SYRS: Kapitalisasi marang pendapatan|TBIO - Multiplikator P/S|TRACON Pharmaceuticals, Inc. (TCON) - Rasio rega marang pendapatan|UBX - Koefisien rega marang pendapatan
